Drug intelligence / Profile preview

anti-BCMA-CAR2

Development stage: Unknown
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Anti-BCMA-CAR2 is a second-generation chimeric antigen receptor (CAR) T-cell therapy approved by the US FDA for the treatment of multiple myeloma. This cell therapy involves engineering a patient's T cells to express a CAR that specifically targets B-cell maturation antigen (BCMA), a protein found on the surface of malignant plasma cells. The engineered T cells then recognize and eliminate these malignant BCMA-expressing cells.

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on anti-BCMA-CAR2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-BCMA-CAR2.

Explore the full profile